Treatment options in androgen-independent prostate cancer

Cancer Investigation

Volumn 17, Issue 2, 1999, Pages 137-144

  Lara Jr , Primo N ^a   Meyers, Frederick J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen independent; Chemotherapy; Hormone refractory; Prostate cancer; Treatment

Indexed keywords

AMINOGLUTETHIMIDE; BICALUTAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; ESTRAMUSTINE; FLAVOPIRIDOL; HYDROCORTISONE; KETOCONAZOLE; MARIMASTAT; MEGESTROL ACETATE; METALLOPROTEINASE INHIBITOR; PREDNISONE; PROTEIN BCL 2; PROTEIN P53; ROQUINIMEX; SURAMIN; THAPSIGARGIN;

ANGIOGENESIS; ANTIGEN EXPRESSION; BEAM THERAPY; CANCER HORMONE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REMISSION; REVIEW; TREATMENT OUTCOME;

EID: 0344572787     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357909909011728     Document Type: Review

References (72)

1. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998.
2. Gittes R: Carcinoma of the prostate. N Engl J Med 324:236-245, 1991.
3. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993.
4. Small EJ, Carroll PR: Prostate specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408-410, 1994.
5. Jenster G, van der Korput HA, van Vroonhoven C, et al: Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396, 1991.
6. Taplin M, Bubley G, Shuster T, et al: Mutation of the androgen receptor gene in metastatic androgen independent prostate cancer. N Engl J Med 332:1393-1398, 1995.
7. Hobisch A, Culig Z, Radmayr C, et al: Distant metastases form prostate carcinoma express androgen receptor protein. Cancer Res 55:3068-72, 1995.
8. De Vere White R, Meyers F, Chi SG, et al: Human androgen receptor expression following androgen ablation. Eur Urol 31:1-6, 1997.
9. Bubley G, Balk S: Treatment of metastatic prostate cancer: lessons from the androgen receptor. Hematol Oncol Clin North Am 10:713-725, 1996.
10. Chi SG, de Vere White RW, Meyers FJ, et al: p53 in prostate cancer: frequently expressed transition mutations. J Natl Cancer Inst 86:926-933, 1994.
11. McDonell TJ, Navone NM, Troscoso P, et al: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569-74, 1997.
12. Porter A, McEwan A, Powe J, et al: Results of a randomized phase III trial to evaluate the efficacy of strontium 89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993.
13. Johnson DE, Haynie TP: Phosphorus-32 for intractable pain in carcinoma of the prostate. Urology 9:137-139, 1997.
14. Cheung A, Driedger AA: Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate. Radiology 134:209-212, 1980.
15. Ahonen A, Joensuu H, Hiltunen J, et al: Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 38(4 Suppl):123-127, 1994.
16. Collins C, Eary JF, Donaldson G, et al: Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34:1839-1844, 1993.
17. Sandeman TF, Budd RS, Martin JJ: Samarium-153-labelled EDTMP for bone marrow metastases from cancer of the prostate. Clin Oncol (R Coll Radiol) 4:160-164, 1992.
18. Robinson RG, Preston DF, Schiefelbein M, et al: Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274:420-424, 1995.
19. Maxon HR, Schroder LE, Hertzberg VS, et al: Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 32:1877-1881, 1991.
20. Srivastava SC, Atkins HL, Krishnamurthy G, et al: Treatment of metastatic bone pain with Tin-117m stannic diethyleneamine-pentacetic acid: a phase I/II clinical study. Clin Cancer Res 4:61-68, 1998.
21. Small E, Vogelzang N: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15:382-388, 1997.
22. Sartor O, Cooper M, Weinberger M, et al: Surprising activity of flutamide withdrawal, when combined with aminogluthetimide, in treatment of hormone refractory prostate cancer. J Natl Cancer Inst 86:222-227, 1994.
23. Scher HI, Liebertz C, Kelly WK, et al: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15:2928-2938, 1997.
24. Liebertz C, Kelly W, Theodoulou M, et al: High dose Casodex for prostate cancer: PSA declines in patients with flutamide withdrawal responses. Proc Am Soc Clin Oncol 15:262, 1996.
25. Dawson NA, Small EJ, Winer EP, et al: Megestrol acetate in men with hormone refractory prostate cancer: prostate specific antigen response and antiandrogen withdrawal data: a Cancer and Leukemia Group B study. Proc Am Soc Clin Oncol 15:241, 1996.
26. Kelly W, Curley T, Leibertz C, et al: Prospective evaluation of hydrocortisone and suramin in patients with androgen independent prostate cancer. J Clin Oncol 13:2208-2213, 1995.
27. Tannock I, Fospodarowicz M, Meakin W, et al: Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989.
28. Gerber GS, Chodak GW: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory prostate cancer. J Urol 144:1177-1179, 1990.
29. Sinibaldi V, Carducci M, Abeloff M, et al: Experience with casodex in patients with stage D3 prostate cancer. Proc Am Soc Clin Oncol 16:313a, 1997.
30. Mani S, Vogelzang N: Is off protocol chemotherapy for androgen independent carcinoma of the prostate warranted? Hematol Oncol Clin North Am 10:749-768, 1996.
31. Kreis W: Current chemotherapy and future directions in research for the treatment of advanced hormone refractory prostate cancer. Cancer Invest 13:296-312, 1995.
32. Stearns ME, Tew KD: Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 89:331-342, 1988.
33. Loening SA, Beckley S, Brady MF, et al: Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 129:1001-1006, 1983.
34. Murphy GP, Gibbons RP, Johnson DE, et al: The use of estramustine phosphate and streptosozin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 118:288-291, 1977.
35. Soloway MS, deKernion J, Gibbons R, et al: Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125:664-667, 1981.
36. Soloway MS, Beckley S, Brady M, et al: a comparison of estramustine phosphate versus cisplatinum alone versus estramustine phosphate plus cisplatinum in patients with advanced hormone refractory prostate cancer who had extensive irradiation to the pelvis and lumbosacral area. J Urol 129:56-61, 1983.
37. DeKernion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostate cancer. Urology 31:312-317, 1988.
38. Murphy GP, Gibbons RP, Johnson DE, et al: The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostate cancer patients who have received prior irradiation. J Urol 121:763-765, 1979.
39. Schmidt JD, Scott WW, Gibbons RP, et al: Comparison of procarbazine, imidazole-carbamide, and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 121:185-189, 1979.
40. Raghavan D, Cox K, Pearson BS, et al: Oral cyclophosphamide for the management of hormone refractory prostate cancer. Br J Urol 72:625, 1993.
41. Von Roemeling R, Fisher H, Horton J. Daily oral cyclophosphamide is effective in hormone refractory prostate cancer: a phase I/II study. Proc Am Soc Clin Oncol 11:213, 1992.
42. Mahjoubi M, Azalo M, Ghosh M, et al: Phase II trial of ifosfamide in the treatment of metastatic hormone refractory patients with prostate cancer. Cancer Invest 8:477-479, 1990.
43. Torti F, Aston D, Lum B, et al: Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 11:2167, 1993.
44. Kantoff PW, Bryant P, Block C, et al: Fourteen day constant infusion of mitoxantrone HCL for hormone refractory carcinoma of the prostate (HRCaP): a pilot dose finding study. Proc Am Soc Clin Oncol 10:175, 1991.
45. Knopf R, Knopf K, Ganesh L, et al: Pilot study of low dose weekly mitoxantrone as a single agent in widely metastatic hormone refractory prostate cancer. Proc Am Soc Clin Oncol 12:250, 1993.
46. Osborne CK, Drelichman A, Von Hoff DD, et al: Mitoxantrone: modest activity in a phase II trial in advanced prostate cnacer. Cancer Treat Rep 67:1133, 1983.
47. Roth BJ, Yeap BY, Wilding G, et al: Taxol in advanced, hormone refractory carcinoma of the prostate. Cancer 72:2457-60, 1993.
48. Hudes GR, Kosierowski R, Greenberg R, et al: Phase II study of topotecan in metastatic hormone refractory prostate cancer. Invest New Drugs 13:235-240, 1995.
49. De Souza P, Cooper M, Inondi A, et al: 9-Aminocaptothecin, a topoisomerase inhibitor with preclinical axtivity against prostate cancer. Proc Am Assoc Cancer Res 37:430, 1996.
50. Morant R, Ackerman D, Trinkler F, et al: Gemcitabine in hormone refractory metastatic prostatic carcinoma - a phase II study of the SAKK. Proc Am Soc Clin Oncol 16:311 a, 1997.
51. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adeno-carcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994.
52. Hudes GR, Greenberg R, Krigel RL, et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992.
53. Hudes GR, Nathan F, Khater C, et al: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156-3163, 1997.
54. Petrylak DP, Shelton G, Judge T, et al. Phase I trial of docetaxel (D) + estramustine (E) in androgen-insensitive prostate cancer (AIP). Proc Am Soc Clin Oncol 16:310a, 1997.
55. Siu LL, Moore M. Is there a role for chemotherapy in hormone refractory prostate cancer? Adv Oncol 12:22-29, 1996.
56. Small EJ, Srinivas S, Madhavan S, et al: Use of doxorubicin (D) and dose escalated cyclophosphamide (C) with granulocyte colony stimulating factor (gCSF) in the treatment of hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 13:243, 1995.
57. Walther PJ, Keane TE, Walker AN, et al: Treatment of hormone refractory prostate carcinoma with cisplatin and continuous infusion 5FU. Proc Am Soc Clin Oncol 9:308, 1990.
58. Kantoff PW, Conaway M, Winer E, et al: Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: preliminary results from a prospective randomized Cancer and Leukemia Group B study (9182) comparing chemotherapy to best supportive care. Proc Am Soc Clin Oncol 15:2013, 1996.
59. Tannock IF, Osoba D, Stockler M, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1756-1764, 1996.
60. LaRocca RV, Stein CA, Danesi R, Myers CE: Suramin, a novel antitumor compound. J Steroid Biochem Mol Biol 37:893-898, 1990.
61. Myers C, Cooper M, Stein C, et al: Suramin: a novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992.
62. Dawson DA, Figg WD, Brawley OW, et al: Phase II study of suramin plus animogluthetimide in two cohorts of patients with androgen independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res 4:37-44, 1998.
63. Eisenberger MA, Reyno LM, Jodrell DI, et al: Suramin, an active drug for prostate cancer: interim observations in a Phase I trial. J Natl Cancer Inst 85:611-621, 1993.
64. Reyno LM, Egorin MJ, Eisenberger MA, et al: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-2195, 1995.
65. Kelly WK, Curley T, Leibertz C, et al: Prospective evaluation of hydrocortisone and suramin in patients with androgen independent prostate cancer. J Clin Oncol 13:2208-2213, 1995.
66. Kobayashi K, Vokes EE, Vogelzang N, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196-2207, 1995.
67. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al: Phase I and clinical evaluation of pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13:2174-2186, 1995.
68. Bowden CJ, Gigg WD, Dawson NA, et al: A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chermother Pharmacol 39:1-8, 1996.
69. Dawson NA, Cooper MR, Figg WD, et al: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76:453-462, 1995.
70. Solvin S, Larson S, Divgi C, et al: Monoclonal antibody (MoAb) 1131-CC49 and Interferon gamma (INF-G): efficacy and therapeutic utility of a phase II trial in hormone insensitive prostate cancer (HIPC). Proc Am Soc Clin Oncol 15:444, 1996.
71. Roth BJ: New therapeutic agents for hormone-refractory prostate cancer. Semin Oncol 23(6 Suppl 14):49-55, 1996.
72. O'Connor PM, Jackman J, Bae I, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300, 1997.